Ross Thurston
About Ross Thurston
Ross Thurston is a Scientist II and Bio Assays Team Leader at Asklepios BioPharmaceutical, Inc., where he has worked since 2022. He has extensive experience in analytical development and bioassays, particularly in the context of gene therapy.
Current Role at Asklepios BioPharmaceutical
Ross Thurston currently serves as Scientist II and Bio Assays Team Leader at Asklepios BioPharmaceutical, Inc. (AskBio) in Durham, North Carolina. He has held this position since 2022, leading the development and transfer of cell-based potency assays for AskBio's AAV gene therapy pipeline. His role involves ensuring that the bioassays meet regulatory and Chemistry, Manufacturing, and Controls (CMC) objectives.
Previous Experience at Asklepios BioPharmaceutical
Prior to his current role, Ross Thurston worked at Asklepios BioPharmaceutical as Scientist II for 10 months in 2022 and as Scientist I from 2020 to 2022. During his time at AskBio, he contributed to various projects focused on bioassay development within the gene therapy sector.
Professional Background in Biotechnology
Ross Thurston has a diverse background in biotechnology, having worked at several organizations prior to his tenure at AskBio. He was an Associate Scientist in Cell Culture Development at Biogen Idec for 10 months in 2013-2014. He then joined Argos Therapeutics as an Assay Development Associate from 2014 to 2017, followed by a position as Scientist II at BioAgilytix from 2017 to 2020.
Educational Qualifications
Ross Thurston earned a Bachelor of Science degree in Biology from Siena College, where he studied from 2004 to 2008. This educational background laid the foundation for his career in the biotechnology field, particularly in analytical development and gene therapy.
Expertise in Gene Therapy and Bioassays
Ross Thurston possesses expertise in analytical development, specifically within the field of gene therapy. His work focuses on developing bioassays that comply with regulatory standards and CMC objectives, contributing to the advancement of gene therapy technologies.